Ascendis Pharma A/S Overview
Valuation check: ASND's ROE is 52.64%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow52.64%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Ascendis Pharma A/S's return on equity stands at 52.64%. That is above the Healthcare sector average of 20.86%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Ascendis Pharma A/S sits higher the Healthcare benchmark (20.86%) with a ROE of 52.64%. That is roughly 152.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 52.64% for Ascendis Pharma A/S means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Ascendis Pharma A/S's ROE evolved across reporting periods, while the comparison chart places ASND next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Ascendis Pharma A/S's reading of 52.64% (sector avg 20.86%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
